Mitsubishi Tanabe Pharma Corp., of Osaka, Japan, said the FDA accepted its new drug application for edaravone (MCI-186), an antioxidant free radical scavenger formulated for intravenous treatment of amyotrophic lateral sclerosis (ALS), and set a PDUFA date of June 16, 2017. If approved, the medicine will be commercialized in the U.S. under the brand name Radicava through the newly formed unit, MT Pharma America Inc. The edaravone NDA was supported by a research program in patients diagnosed with ALS in Japan.